The role of chemotherapy in the management of carcinoma of the cervix

Cancer Journal

Volumn 9, Issue 5, 2003, Pages 425-432

  Thigpen, Tate ^a,b,c  

^a University of Mississippi Medical Center ^*

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Adenosquamous tumors; Cervical carcinoma; Chemotherapy; FIGO; Recurrence; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL;

ARTICLE; CANCER SCREENING; CHEMOTHERAPY; DRUG DOSE REGIMEN; HUMAN; METASTASIS; PELVIS; PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; CANCER STAGING; FEMALE; PATHOLOGY; PELVIS TUMOR; REVIEW; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PELVIC NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 1542439958     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200309000-00013     Document Type: Article

References (121)

1. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the world wide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54: 594-606.
3. Thigpen JT. Single agent chemotherapy in carcinoma of the cervix. In: Surwit E, Alberts D, eds. Cervix cancer. Boston: Martinus Nijhoff, 1987:119-1936.
4. Thigpen T. Chemotherapy in the management of advanced or recurrent carcinoma of the cervix. In: Rubin S, Hoskins W, eds. Cervical cancer and preinvasive neoplasia. Philadelphia: Lippincott-Raven, 1996.
5. Muscato MS, Perry MC, Yarbro JW. Chemotherapy of cervical carcinoma. Semin Oncol 1982;9:373-387.
6. Omura GA, Velez-Garcia E, Birch R, writing for the Southeastern Cancer Study Group. Phase II randomized study of doxorubicin, vincristine, and 5-FU versus cyclophosphamide in advanced or recurrent cervical and endometrial carcinoma. Cancer 1981;65: 901-903.
7. Thigpen T, Vance RB, Balducci L, BlessingJ. Chemotherapy in the management of advanced or recurrent cervical and endometrial carcinoma. Cancer 1981 1981;48:658-665.
8. Stehman FB, Blessing JA, McGehee R, Barrett RJ. A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1989;7:1892-1895.
9. Lira-Puerto V, Piccart M, Wiernik P, et al. A comparison of US and Mexican experience with single drug therapy in advanced cervical cancer (NCI-PAHO and ECOG study). Proc Am Soc Clin Oncol 1985;4:117.
10. Stehman FB, Blom J, Blessing JA, et al. Phase II trial of galactitol 1,2:5,6-dianhydro in the treatment of advanced gynecologic malignancies: a Gynecologic Oncology Group studies. Gynecol Oncol 1983;15:381-390.
11. Sutton GP, Blessing JA, Photopoulos G, et al. Phase II experience with ifosfamide/mesna in gynecologic malignancies:preliminary report of Gynecologic Oncology Group studies. Semin Oncol 1989;16(suppl 3):68-72.
12. Sutton GP, Blessing JA, Adcock L, et al. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix: a Gynecologic Oncology Group study. Invest New Drugs 1989;7:341-343.
13. Thigpen T, Vance R, Khansur T, Malamud F. The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix (review). Semin Oncol 1996;23(3 suppl 6):56-64.
14. Arseneau J, Blessing J, Stehman F, McGehee R. A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix. Invest New Drugs 1986;4:187-191.
15. McGuire WP, Arseneau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous cell carcinoma of the uterine cervix: Gynecologic Oncology Group study. J Clin Oncol 1989;7:1462-1468.
16. Thigpen T, Shigleton H, Homesley H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix. Cancer 1981;48:1079-1085.
17. Bonomi P, Blessing JA, DiSaia PJ, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology study. J clin Oncol 1985;3:1079-1085.
18. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989;32: 198-202.
19. Cohen C, Castro-Marin A, Deppe G, et al. Chemotherapy of advanced or recurrent cervical cancer with platinum II-a preliminary report. Proc Am Soc Clin Oncol 1978;19:401.
20. Baker L. Cisplatin in treatment of cervical and endometrial cancer patients. In: Prestayko J, Crooke S, Carter S, eds. Cisplatin: current status and new developments. New York: Academic Press, 1980:403-409.
21. Baker L, Boutselis J, Alberts D, et al. Combination chemotherapy for patients with disseminated carcinoma of the uterine cervix. Proc Am Soc Clin Oncol 1985;4:120.
22. Wasserman T, Carter S. The integration of chemotherapy into combined modality treatment of solid tumors. VIII. Cervical cancer. Cancer Treat Rev 1977;4:25-46.
23. Cavins J, Geisler H. Treatment of advanced, unresectable, cervical carcinoma already subjected to complete irradiation therapy. Gynecol Onol 1978;6:256-260.
24. Piver M, Barlow J, Xynos F. Adriamycin alone or in combination in 100 patients with carcinoma of the cervix or vagina. Am J Obstet Gynecol 1978;131:311-313.
25. Malkasian G, Decker D, Green S, et al. Treatment of recurrent and metastatic carcinoma of the cervix: comparison of doxorubicin with a combination of vincristine and 5-fluorouracil. Gynecol Oncol 1981;11:235-239.
26. Greenburg B, Kardinal C, Pajek T, Batemen J. Adriamycin versus Adriamycin and bleomycin in advanced epidermoid carcinoma of the cervix. Cancer Treat Rep 1977;61:1383-1384.
27. Wallace H, Hreshchyshyn M, Wilbanks G, et al. Comparison of the therapeutic effect of Adriamycin alone versus Adriamycin plus vincristine versus Adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat Rep 1978;62:1435-1441.
28. Freeman R, Herson J, Wharton T, Rutledge F. Single agent chemotherapy for recurrent carcinoma of the cervix. Cancer Clin Trials 1980;3:345-350.
29. Arseneau JC, Bundy B, Dolan T, et al. Phase II study of Bakers antifol in advanced squamous cell carcinoma of cervix. Am J Clin Oncol 1982;5:61-64.
30. Malkasian G, Decker D, Jorgensen E. Chemotherapy of carcinoma of the cervix. Gynecol Oncol 1977;5:109-120.
31. Takeuchi S, Noda K, Yakushiji M. Late phase II study of CPT-11, topoisomerase I inhibitor in advanced cervical carcinoma (abstract 708). Proc Am Soc Clin Oncol 1992;11:224.
32. Conroy JF, Lewis GC Jr, Blessing JA, et al. ICRF-159 in patients with advanced squamous cell carcinoma of the uterine cervix. AM J Clin Oncol 1984;7:131-133.
33. Asbury RF, Blessing JA, Mortel R, et al. Aminothiadiazole in patients with advanced cervical carcinoma: a phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1987;10: 299-301.
34. Asbury RF, Blessing J, Soper J. A Gynecologic Oncology Group phase II study of amonafide in squamous cell carcinoma of the cervix. Am J Clin Oncol 1994;17:125-128.
35. Bonomi P, Blessing JA, Sedlacek TV, et al. Phase II trial of AMSA in patients with advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Treat Rep 1983;67:197-198.
36. Omura G, Shingleton H, Creasman W, et al. Chemotherapy of advanced gynecologic cancer with nitrosoureas: a randomized trial of CCNU and methyl CCNU in carcinoma of the cervix, corpus, vagina, vulva and tube. Cancer Treat Rep 1978;62: 833-635.
37. Slayton RE, Blessing JA, Stehman FB, Malfetano J. Phase II clinical trial of diaziquone in the treatment of patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Treat Rep 1986;70:1127-1128.
38. Roberts JA, Blessing JA, McGehee R, et al. Phase II trial of dichloromethotrexate in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Treat Rep 1987;71:1295-1296.
39. Jacobs A, Blessing J, Munoz A. A phase II trial of didemnin b in advanced or recurrent cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1991;44:268-270.
40. Weiss GR, Liu PY, O'Sullivan J, et al. A randomized phase II trial of trimetrexate or didemin b for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group tria. Gynecol Oncol 1992;445:303-306.
41. Muss HB, Blessing JA, Yordan E, Beecham J. Phase II study of esorubicin in advanced or metastatic squamous-cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1990;13:191-193.
42. Lincoln S. Personal communication of GOG data, 2000.
43. McGuire WP, Blessing JA, Yordan E, Beechman J. Phase II study of esorubicin in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Invest New Drugs 1989;7:235-238.
44. Slayton RE, Creasman WT, Perry W, et al. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group study. Cancer Treat Rep 1979;63:2089-2092.
45. Manetta A, Blessing J, Mann W, Smith D. A phase II study of fazaravine in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1995;18:156-157.
46. Look K, Blessing J, Muss H, et al. 5-fluorouracil and leucovorin in the treatment of recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 19995;18:156-157.
47. Look K, Blessing J, Gallup D, et al. A phase II trial of 5-fluorouracil and high dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1992;15:497-499.
48. Malfetano J, Blessing J, Homesley H, et al. A phase II trial of gallium nitrate in advanced or recurrent squamous cell cearcinoma of the cervix. A Gynecologic Oncology Group study. Invest New Drugs 1991;9:109-111.
49. McGuire WP, Blessing JA, Hatch K, DiSaia PJ. A phase II study of CHIP in advanced squamous cell carcinoma of the cervix. Invest New Drugs 1986;4:181-186.
50. Thigpen JT, Ehrlich CE, Conroy J, Blessing JA. Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. Am J Clin Oncol 1994;6:427-430.
51. Sutton G, Blessing J, Gallup D, Homesley H. Phase II trial of menogaril in patients with squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1994;52: 229-231.
52. Look K, Blessing J, Williams L, Morris M. A phase II trial of merbarone (NSC 336628) as salvage therapy for squamous cell carcinoma of the cervix. A Gynecologic Oncology study. Am J Clin Oncol 1995;18:441-443.
53. Thigpen T, Blessing J, Gallup D, et al. Phase II trial of mitòmycin-C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1995;57:376-379.
54. Muss HB, Sutton GP, Bundy B, Hatch KD. Mitoxamrone in patients with advanced cervical carcinoma: a phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1985;8:312-315.
55. McGuire WP, Blessing JA, Hatch KD, Berman ML. Phase II study of N-methylformamide in patients with advanced squamous cancer of the cervix. Invest New Drugs 1990;8:195-197.
56. Muss HB, Bundy B, DiSaia PJ, et al. PALA in advanced carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1984;7:741-744.
57. Thigpen JT, Blessing J, Homesley H, Adcock L. Phase II trial of piperazinedione in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. Am J Clin Oncol 1983; 6:423-426.
58. Lincoln S. Personal communication of GOG data, 2000.
59. Muss HB, Bundy BN, Yazigi R, Yordan E. Teniposide in squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Cancer Treat Rep 1987;71:873-874.
60. Feun L, Blessing J, Barrett R, Hanjani P A phase II trial of tricyclic nucleoside phosphate (TCN-P) in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1993;16:506-508.
61. Sutton GP, Blessing JA, Barnes W, Ball H. Phase II study of vinblastine in previously treated squamous carcinoma of the cervix: a Gynecologic Oncology Group study. An J Clin Oncol 1990; 13:470-471.
62. Slavik M, Muss H, Blessing JA. Phase II clinical study of Yoshi 864 in squamous cell carcinoma of the uterine cervix. Cancer Treat Rep 1983;67:195-196.
63. Muderspach LI, Blessing JA, Levenback C and Moore JL. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic Oncology Group study. Gynec Oncol 2001;81:213-215.
64. Morris M, Brader K, Levenback C, et al. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1998;16:1094-1098.
65. Plaxe S. Personal communication of GOG data, 2000.
66. Schilder R. Personal communication of GOG data, 2000.
67. McGuire WP, Blessing J, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol 1996;14:792-795.
68. Rose P, Blessing J, Gershenson D, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1999;17:2676-2680.
69. Rose, PG, Blessing JA, Van Le L, Waggoner S. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecology Oncology Group study. Gynecol Oncol 1998;70:263-266.
70. Look KY, Blessing JA, Nelson BE, et al. A phase II trial of isotretinoin and alpha interferon in patients with recurrent squamous cell carcinoma of cervix: a Gynecology Oncology Group study. Am J Clin Oncol 1998;21:591-594.
71. Brenner D. Combination chemotherapy of advanced cervix cancer. In: Surwit E, Alberts D, eds. Cervix cancer. Boston: Martinus Nijhoff, 1987:137-160.
72. Edmondson J, Johnson P, Wieand HS, et al. Phase II studies of bleomycin, cyclophosphamide, doxorubicin and cisplatin, and bleomycin and cisplatin in advanced cervical carcinoma. Am J Clin Oncol 1988;11:149-151.
73. Jobson V, Homesley H, Muss H, et al. Chemotherapy of advanced squamous carcinoma of the cervix: a phase I-II study of high-dose cisplatin and cyclophosphasmide. Am J Clin Oncol 1984; 7:341-345.
74. Bezwoda WR, Nissenbaum M, Derman DR Treatment of metastatic and recurrent cervix cancer with chemotherapy-a randomized trial comparing hydroxyurea with cis-diamminedichloroplatinum plus methotrexate. Med Pediatr Oncol 1986;14:17-19.
75. Bonomi P, Yordan E, Blessing J. Phase I trial of cisplatin and razoxane in advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 1988;11:1-2.
76. Vogl S, Moukhtar M, Kaplan B. Chemotherapy for advanced cervical cancer with methotrexate, methotrexate, bleomycin, and cis-diamminedichloraoplatinum. Cancer Treat Rep 1979;63: 1005-1006.
77. nd ed. New York: Wiley-Liss, 1990:121-153.
78. Friedlander M, Kaye S, Sullivan A, et al. Cervical Carcinoma: a drug-responsive tumor-experience with combined cisplatin, vinblastine, and bleomycin therapy. Gynecol Oncol 1983;16: 276-281.
79. Chauvergne J, Heron J, Mayer F, et al. Chemotherapy of cancers of the uterine cervix with a combination of bleomycin, mitomycin, cisplatin and etoposide. Bull Cancer 1993;80:70-79.
80. Coleman R, Harper P, Gallagher C, et al. A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Cheomther Pharmacol 19886;18:280-283.
81. Weiss G, Green S, Hannigan E, et al. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecol Oncol 1990;37:354-358.
82. Weiss GR, Green S, Hannigan E, et al. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix. A Southwest Oncology Group trial. Gynecol Oncol 1989;34:357-359.
83. Bonomi P, Blessing J, Ball H, et al. A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncol 1989;34: 357-359.
84. Omura G, Hubbard J, Hatch K. Limited tolerance for high dose cisplatin plus doxorubicin after radiotherapy for female pelvic cancer: a Gynecologic Oncology Group pilot study, Am J Clin Oncol 1985;8:347-349.
85. Fine S, Sturgeon J, Gospodarowicz M, et al. Treatment of advanced carcinoma of the cervix with methotrexate, Adriamycin, cisplatin. Proc Am Soc Clin Oncol 1983;2:154.
86. Wheelock J, Krevs H, Goplerud D, Myers N. Cisplatinum, doxorubicin, and methotrexate for cervical cancer. Obstet Gynecol 1985;66:410-412.
87. Edmondson J, Johnson P, Wieand HS, et al. Phase II studies of bleomycin, cyclophosphamide, doxorubicin and cisplatin, and bleomycin and cisplatin in advanced cervical carcinoma. Am J Clin Oncol 1988;11:149-151.
88. Chiara S, Consoli R, Falcone A, et al. Cisplatin and 5-fluorouracil in advanced and recurrent cervical cancer. Tumori 1988;74: 471-474.
89. Cervellino JC, Araujo CE, Sanchex O, et al. Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. Acta Oncol 1995;34:257-259.
90. Kuhnle H, Meerpohl H, Eiermann W, et al. Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer. Cancer Chemother Pharmacol 1990;26:S33-S35.
91. Ramm K, Vergote I, Kaem J, Trope C. Bleomycin-ifosfamide-cisplatinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look. Gynecol Oncol 1992;46:203-207.
92. Tay Sk, Lai FM, Soh LT, et al. Combined chemotherapy using cisplatin ifosfamide and bleomycin (PIB) in the treatment of advanced and recurrent cervical carcinoma. Aust N Z J Obstet Gynecol 1993;32:263-266.
93. Buxton E, Meanwell C, Hilton C, et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 1989;81:359-361.
94. Kumar L, Bhargava V. Chemotherapy in recurrent and advanced cervical cancer. Gynecol Oncol 1991;40:107-111.
95. Murad AM, Triginelli SA, Ribalta JCL. Phase II trial of bleomycin, ifosfamide, and carboplatin in metestatic cervical cancer. J Clin Oncol 1994;12:55-59.
96. Kredentser DC. Etoposide, ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. Gynecol Oncol 1991;43:145-148.
97. Filtenborg TA, Hansen HH, Aage ES, Rorth M. A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix. Ann Oncol 1993; 4:485-488.
98. Omura GA, Blessing JA Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifofamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997;17:165-171.
99. Moore DH, McQuellon RP, Blessing JA et al. A randomized phase III study of cisplatin versus cisplatin plus paclilaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Proc Amer Soc Clin Oncol 2001;20:201a (abstr).
100. Bloss JD, Blessing JA, Behrens BC et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2002;20:1832-1837.
101. Thigpen JT, Blessing JA, Fowler WC Jr, Hatch K. Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study Cancer Treat Rep 1986;70:1097-1100.
102. Slayton RE, Blessing JA, Homesley HD. Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Treat Rep 1984;68:1513-1514.
103. Stehman FB, Blessing JA, Homesley HD, et al. Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma: a Gynecologic Oncology Group study. Invest New Drugs 1984;2:331-333.
104. Homesley HD, Blessing JA, Berman M. ICRF-159 in patients with advanced nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1986;9: 325-326.
105. Muss HB, Bundy BN, Homesley HD, Wilbanks G. Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix. Invest New Drugs 1987;5:199-202.
106. Slayton RE, Blessing JA, Rettenmaier M, Ball H. A phase Ii clinical trial of diaziquone in the treatment of patients with recurrent adenocarcinoma and adenosquamous carcinoma of the cervix: a Gynecologic Oncology Group study. Invest New Drugs 1989;7: 337-340.
107. Asbury RF, Blessing JA, DiSaia PJ, Malfetano J. Aminothiadiazole in patients with advanced nonsquamous carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1989;12:375-377.
108. Muss HB, Bundy BN, Given FT, Stehman FB. Teniposide in patients with non-squamous-cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1990;13:117-118.
109. Sutton G, Blessing J, Anderson B, et al. Phase II trial of ifosfamide and mesna in patients with recurrent or advanced nonsquamous carcinoma of the cervix. Proc Am Soc Clin Oncol 1990;9:167.
110. Malfetano J, Blessing J, Homesley H. A phase II trial of gallium nitrate in nonsquamous cell carcinoma of the cervix. Am J Clin Oncol 1995;18:495-497.
111. Curtin JP, Blessing JA, Webster KD et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2001;19:1275-1278.
112. Steel GG, Peckman MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979;5:85-91.
113. Sinclair WK. The combined effect of hydroxyurea and x-rays on Chinese hamster cells in vitro. Cancer Res 1968:28:198-206.
114. Phillips RA, Tolmach LJ. Repair of potentially lethal damage in x-irradiated HeLa cells. Radiat Res 1966.29:413-432.
115. Fu KK. Biological basis for the interaction of chemotherapeutic agents and radiation therapy. Cancer 1985:55(suppl): 2123-2130.
116. Whitney CW, Sause W, Bundy BN et. Al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as a adjunct 10 radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17:1339-1348.
117. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Eng J Med 1999;340:1137-1143.
118. Rose PG, Bundy BN, Watkins EB, et. al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Eng J Med 1999;340:1144-1153.
119. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999:340:1154-1161.
120. th Annual Society of Gynecologic Oncology meeting in San Francisco, 1999.
121. Bloss JD, Lucci JA 3rd, DiSaia PJ, et al. A phase II trial of neoadjuvant chemotherapy prior to radical hysterectomy and/or radiatoin therapy in the management of advanced carcinoma of the uterine cervix. Gyecol Oncol 1995:59;105-110.